DS
TMCI icon

David Shaw’s Treace Medical Concepts TMCI Stock Holding History

David Shaw’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.32M Sell
583,277
-257,992
-31% -$709K ﹤0.01% 3072
2026
Q1 		$1.13M Buy
841,269
+211,139
+34% +$421K ﹤0.01% 3361
2025
Q4 		$1.54M Sell
630,130
-131,203
-17% -$570K ﹤0.01% 3249
2025
Q3 		$5.11M Sell
761,333
-62,023
-8% -$405K ﹤0.01% 2191
2025
Q2 		$4.84M Sell
823,356
-96,818
-11% -$631K ﹤0.01% 2064
2025
Q1 		$7.72M Sell
920,174
-195,652
-18% -$1.76M 0.01% 1583
2024
Q4 		$8.3M Sell
1,115,826
-28,140
-2% -$188K 0.01% 1622
2024
Q3 		$6.64M Buy
1,143,966
+382,797
+50% +$2.46M 0.01% 1729
2024
Q2 		$5.06M Buy
761,169
+484,730
+175% +$3.92M ﹤0.01% 1839
2024
Q1 		$3.61M Buy
276,439
+129,863
+89% +$1.73M ﹤0.01% 2147
2023
Q4 		$1.87M Buy
146,576
+78,327
+115% +$791K ﹤0.01% 2720
2023
Q3 		$895K Sell
68,249
-172,714
-72% -$3.16M ﹤0.01% 3130
2023
Q2 		$6.16M Buy
240,963
+101,899
+73% +$2.63M 0.01% 1708
2023
Q1 		$3.5M Buy
+139,064
New +$3.27M ﹤0.01% 2248

Other funds holding TMCI

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
CBU
CIBC Bancorp USA Chicago, Illinois $82.3B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

David Shaw's TMCI Position: Q2 2026 in Review

David Shaw reduced its Treace Medical Concepts (TMCI) stake by 31% in Q2 2026, selling an estimated $709K and leaving 583,277 shares worth $2.32M. The position accounts for ﹤0.01% of the portfolio, ranked #3072.

David Shaw first reported a position in TMCI in Q1 2023 and has held it in 14 quarters since. The position peaked at $8.3M in Q4 2024. 117 funds tracked by Wall St. Rank hold TMCI as of Q2 2026.

  • David Shaw held 583,277 shares of Treace Medical Concepts worth $2.32M as of Q2 2026.
  • David Shaw sold 257,992 Treace Medical Concepts shares in Q2 2026, an estimated $709K.
  • Treace Medical Concepts made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3072 holding.
  • David Shaw first reported a position in Treace Medical Concepts in Q1 2023 and has held it in 14 quarters since.
  • David Shaw's Treace Medical Concepts position peaked at $8.3M in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.